A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults

NCT06137729 | Terminated Phase 1 FDA Drug

• 2 other identifiers: C54710012023-507354-32-00
• Study Type: interventional
• Target: 37
• Locations: 1 country
• Sites: 1

Brief Summary

The purposes of the study are as follows:

• To understand how safe and tolerable are different amounts of study medicine (PF-07899895).
• To measure the amount of PF-07899895 in blood after the medicine is taken by mouth. The study is seeking participants who:
• Are male or female of 18 to 65 years of age.
• Are in good health condition.
• Have not had viral infections (HIV, HBV, or HCV). HIV, human immunodeficiency virus. - HBV, human hepatitis B virus. HCV, human hepatitis C virus.
• Have tested negative for tuberculosis. Participants will receive either PF-07899895 or placebo (dummy pill) by chance. In the first part of the study (Part A):
• each participant will receive a total of up to 5 doses of the medicine or placebo with at least 5 days between each dose.
• after each dose, participants will stay in study clinic for 3 to5 days. In the second part of the study (Part B): \- each participant will need to take 10 days of dosing and will stay in the study clinic for clinical checks for 13 days. In the third part of the study (Part C):
• In SD cohort, each participant will receive a total of up to 5 doses of the medicine or placebo with at least 7 days between each dose. After each dose, participants will stay in study clinic for 5 days.
• In MD cohorts, each participant will need to take 10 days of dosing and will stay in the study clinic for clinical checks for 13 days. The planned duration of participation from screening to follow-up in:
• Part A of the study is up to 15 to 18 weeks.
• Part B of the study is up to 11 weeks.
• Part C of the study is up to 15 to 18 weeks. Participants will also have their blood collected by the study doctors for several times.

Conditions

Healthy

Outcome Measures

Primary Outcomes (5)

• AE observed after single or multiple doses

  number of participants experience AE or SAEs.

  Day 1 up to Day 28 (Part A)/Day 1 up to Day 38 (Part B)

• Laboratory abnormalities following single or multiple ascending doses

  number of participants with laboratory abnormalities

  Day 1 up to Day 28 (Part A)/Day 1 up to Day 38 (Part B)

• Vital sign changes following single or multiple ascending doses

  Number of participants with change from baseline in vital signs

  Day 1 up to Day 28 (Part A)/Day 1 up to Day 38 (Part B)

• ECG changes following single or multiple ascending doses

  Number of participants with change from baseline in electrocardiogram (ECG) parameters

  Day 1 up to Day 28 (Part A)/Day 1 up to Day 38 (Part B)

• Changes in physical examination after single or multiple ascending doses

  Number of participants with change from baseline in physical examinations (PE)

  Day 1 up to Day 28 (Part A)/Day 1 up to Day 38 (Part B)

Secondary Outcomes (14)

• Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast)

  Day 1 up to Day 3 (Part A)

• Dose normalized AUClast divided by dose (AUClast(dn))

  Day 1 up to Day 3 (Part A)

• Maximum Observed Plasma Concentration (Cmax)

  Day 1 (Part A)/Day 1 and Day 10 (Part B)

• Dose normalized Cmax divided by dose (Cmax(dn))

  Day 1 (Part A)/Day 1 and Day 10 (Part B)

• Time to Reach Maximum Observed Plasma Concentration (Tmax)

  Day 1 (Part A)/Day 1 and Day 10 (Part B)

Study Arms (2)

PF-07899895

EXPERIMENTAL

Participants will receive single or multiple ascending oral doses of PF-07899895.

Drug: PF-07899895

Placebo

PLACEBO COMPARATOR

Participants will receive matching placebo.

Drug: Placebo

Interventions

PF-07899895 DRUG

Participants will receive oral ascending doses.

PF-07899895

Placebo DRUG

Participants will receive matching placebo.

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants, male or female, must be 18 to 65 years of age, inclusive, at the time of signing the ICD.
• BMI of 16 to 32 kg/m2; and a total body weight\>50 kg (110 lb).
• Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs assessments, oral temperature, 12-lead ECGs, and laboratory tests.

You may not qualify if:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
• Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy, bowel resection) or gastrointestinal (GI) transit time (eg, constipation).
• History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb), hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb); positive or indeterminate QuantiFERON test for tuberculosis. Hepatitis B vaccination is allowed.
• Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• History of undesired reactions to the sun (photosensitivity).
• Recent exposure to live or attenuated vaccines within 28 days of the screening visit.
• Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention, with the exception of moderate or strong cytochrome P450 3A (CYP3A) inducers or inhibitors which are prohibited within 14 days plus 5 half-lives prior to the first dose of study intervention.
• Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of PF-07899895 used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study.

Sponsors & Collaborators

• Pfizer: lead

Study Sites (1)

Pfizer Clinical Research Unit - Brussels

Brussels, Bruxelles-capitale, Région de, B-1070, Belgium

Location

Related Links

• To obtain contact information for a study center near you, click here.

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 14, 2023
• First Posted: November 18, 2023
• Study Start: November 17, 2023
• Primary Completion: October 24, 2025
• Study Completion: October 24, 2025
• Last Updated: November 25, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)